| 词条 | Lung cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 释义 |
| name = Lung cancer | synonyms = Lung carcinoma | image = LungCACXR.PNG | caption = A chest X-ray showing a tumor in the lung (marked by arrow) | field = Oncology | symptoms = Coughing (including coughing up blood), weight loss, shortness of breath, chest pains[1] | complications = | onset = ~70 years[2] | duration = | types = Small-cell lung carcinoma (SCLC), non-small-cell lung carcinoma (NSCLC)[3] | causes = | risks = {{hlist|Tobacco smoking|genetic factors|radon gas|asbestos|air pollution[4][5]}} | diagnosis = Medical imaging, tissue biopsy[6][7] | differential = | prevention = | treatment = Surgery, chemotherapy, radiotherapy[7] | medication = | prognosis = Five-year survival rate 17.4% (US)[2] | frequency = 3.3 million affected as of 2015[1] | deaths = 1.7 million (2015)[2] }}Lung cancer, also known as lung carcinoma,[3] is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung.[4] This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body.[5] Most cancers that start in the lung, known as primary lung cancers, are carcinomas.[15] The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC).[6] The most common symptoms are coughing (including coughing up blood), weight loss, shortness of breath, and chest pains.[7] The vast majority (85%) of cases of lung cancer are due to long-term tobacco smoking.[4] About 10–15% of cases occur in people who have never smoked.[8] These cases are often caused by a combination of genetic factors and exposure to radon gas, asbestos, second-hand smoke, or other forms of air pollution.[9][10][11][12] Lung cancer may be seen on chest radiographs and computed tomography (CT) scans.[3] The diagnosis is confirmed by biopsy which is usually performed by bronchoscopy or CT-guidance.[13][14] Avoidance of risk factors, including smoking and air pollution, is the primary method of prevention.[15] Treatment and long-term outcomes depend on the type of cancer, the stage (degree of spread), and the person's overall health.[3] Most cases are not curable.[6] Common treatments include surgery, chemotherapy, and radiotherapy.[3] NSCLC is sometimes treated with surgery, whereas SCLC usually responds better to chemotherapy and radiotherapy.[16] Worldwide in 2012, lung cancer occurred in 1.8 million people and resulted in 1.6 million deaths.[17] This makes it the most common cause of cancer-related death in men and second most common in women after breast cancer.[18] The most common age at diagnosis is 70 years.[2] Overall, 17.4% of people in the United States diagnosed with lung cancer survive five years after the diagnosis,[19] while outcomes on average are worse in the developing world.[20] {{TOC limit|3}}Signs and symptomsSigns and symptoms which may suggest lung cancer include:[7]
If the cancer grows in the airways, it may obstruct airflow, causing breathing difficulties. The obstruction can lead to accumulation of secretions behind the blockage, and predispose to pneumonia.[7] Depending on the type of tumor, paraneoplastic phenomena—symptoms not due to the local presence of cancer—may initially attract attention to the disease. In lung cancer, these phenomena may include hypercalcemia, syndrome of inappropriate antidiuretic hormone (SIADH, abnormally concentrated urine and diluted blood), ectopic ACTH production, or Lambert–Eaton myasthenic syndrome (muscle weakness due to autoantibodies). Tumors in the top of the lung, known as Pancoast tumors, may invade the local part of the sympathetic nervous system, leading to Horner's syndrome (dropping of the eyelid and a small pupil on that side), as well as damage to the brachial plexus.[7] Many of the symptoms of lung cancer (poor appetite, weight loss, fever, fatigue) are not specific.[13] In many people, the cancer has already spread beyond the original site by the time they have symptoms and seek medical attention.[42] Symptoms that suggest the presence of metastatic disease include weight loss, bone pain and neurological symptoms (headaches, fainting, convulsions, or limb weakness).[7] Common sites of spread include the brain, bone, adrenal glands, opposite lung, liver, pericardium, and kidneys.[42] About 10% of people with lung cancer do not have symptoms at diagnosis; these cancers are incidentally found on routine chest radiography.[14] CausesCancer develops after genetic damage to DNA and epigenetic changes. Those changes affect the cell's normal functions, including cell proliferation, programmed cell death (apoptosis), and DNA repair. As more damage accumulates, the risk of cancer increases.[21] SmokingTobacco smoking is by far the main contributor to lung cancer.[9] Cigarette smoke contains at least 73 known carcinogens,[22] including benzo[a]pyrene,[23] NNK, 1,3-butadiene, and a radioactive isotope of polonium – polonium-210.[22] Across the developed world, 90% of lung cancer deaths in men and 70% of those in women during the year 2000 were attributed to smoking.[51] Smoking accounts for about 85% of lung cancer cases.[3]Passive smoking – the inhalation of smoke from another's smoking – is a cause of lung cancer in nonsmokers. A passive smoker can be defined as someone either living or working with a smoker. Studies from the US,[24][25][26] Europe,[27] and the UK[28] have consistently shown a significantly-increased risk among those exposed to passive smoking.[29] Those who live with someone who smokes have a 20–30% increase in risk while those who work in an environment with secondhand smoke have a 16–19% increase in risk.[30] Investigations of sidestream smoke suggest that it is more dangerous than direct smoke.[60] Passive smoking results in roughly 3,400 lung cancer-related deaths each year in the U.S.[26]Marijuana smoke contains many of the same carcinogens as those in tobacco smoke.[31] However, the effect of smoking cannabis on lung cancer risk is not clear.[32][33] A 2013 review did not find an increased risk from light to moderate use.[34] A 2014 review found that smoking cannabis doubled the risk of lung cancer.[35]Radon gasRadon is a colorless and odorless gas generated by the breakdown of radioactive radium, which in turn is the decay product of uranium, found in the Earth's crust. The radiation decay products ionize genetic material, causing mutations that sometimes become cancerous. Radon is the second-most common cause of lung cancer in the US,[36] causing about 21,000 deaths each year.[37] The risk increases 8–16% for every 100 Bq/m³ increase in the radon concentration.[38] Radon gas levels vary by locality and the composition of the underlying soil and rocks. About one in 15 homes in the US have radon levels above the recommended guideline of 4 picocuries per liter (pCi/l) (148 Bq/m³).[70]AsbestosAsbestos can cause a variety of lung diseases such as lung cancer. Tobacco smoking and asbestos both have synergistic effects on the development of lung cancer.[10] In smokers who work with asbestos, the risk of lung cancer is increased 45-fold compared to the general population.[39] Asbestos can also cause cancer of the pleura, called mesothelioma – which actually is different from lung cancer.[40]Air pollutionOutdoor air pollutants, especially chemicals released from the burning of fossil fuels, increase the risk of lung cancer.[9] Fine particulates (PM2.5) and sulfate aerosols, which may be released in traffic exhaust fumes, are associated with a slightly-increased risk.[9][41] For nitrogen dioxide, an incremental increase of 10 parts per billion increases the risk of lung cancer by 14%.[42] Outdoor air pollution is estimated to cause 1–2% of lung cancers.[9]Tentative evidence supports an increased risk of lung cancer from indoor air pollution in relation to the burning of wood, charcoal, dung, or crop residue for cooking and heating.[43] Women who are exposed to indoor coal smoke have roughly twice the risk, and many of the by-products of burning biomass are known or suspected carcinogens.[80] This risk affects about 2.4 billion people worldwide,[43] and it is believed to result in 1.5% of lung cancer deaths.[44] GeneticsAbout 8% of lung cancer is caused by inherited factors.[45] In relatives of people that are diagnosed with lung cancer, the risk is doubled, likely due to a combination of genes.[46] Polymorphisms on chromosomes 5, 6, and 15 are known to affect the risk of lung cancer.[47] Single-nucleotide polymorphisms (SNPs) of the genes encoding the nicotinic acetylcholine receptor (nAChR) – CHRNA5, CHRNA3, and CHRNB4 – are of those associated with an increased risk of lung cancer, as well as RGS17 – a gene regulating G-protein signaling.[47] Other causesNumerous other substances, occupations, and environmental exposures have been linked to lung cancer. The International Agency for Research on Cancer (IARC) states that there is some "sufficient evidence" to show that the following are carcinogenic in the lungs:[48]
Pathogenesis{{See also|Carcinogenesis}}Similar to many other cancers, lung cancer is initiated by either the activation of oncogenes or the inactivation of tumor suppressor genes.[49] Carcinogens cause mutations in these genes that induce the development of cancer.[50] Mutations in the K-ras proto-oncogene cause roughly 10–30% of lung adenocarcinomas.[90][91] Nearly 4% of non-small-cell lung carcinomas involve an EML4-ALK tyrosine kinase fusion gene.[51]Epigenetic changes such as alteration of DNA methylation, histone tail modification, or microRNA regulation may result in the inactivation of tumor suppressor genes.[52] Importantly, cancer cells develop resistance to oxidative stress, which enables them to withstand and exacerbate inflammatory conditions that inhibit the activity of the immune system against the tumor.[53][54]The epidermal growth factor receptor (EGFR) regulates cell proliferation, apoptosis, angiogenesis, and tumor invasion.[90] Mutations and amplification of EGFR are common in non-small-cell lung carcinoma, and they provide the basis for treatment with EGFR-inhibitors. Her2/neu is affected less frequently.[90] Other genes that are often mutated or amplified include c-MET, NKX2-1, LKB1, PIK3CA, and BRAF.[90] The cell lines of origin are not fully understood.[7] The mechanism may involve the abnormal activation of stem cells. In the proximal airways, stem cells that express keratin 5 are more likely to be affected, typically leading to squamous-cell lung carcinoma. In the middle airways, implicated stem cells include club cells and neuroepithelial cells that express club cell secretory protein. Small-cell lung carcinoma may originate from these cell lines[100] or neuroendocrine cells,[7] and it may express CD44.[55] Metastasis of lung cancer requires transition from epithelial to mesenchymal cell type. This may occur through the activation of signaling pathways such as Akt/GSK3Beta, MEK-ERK, Fas, and Par6.[56]DiagnosisPerforming a chest radiograph is one of the first investigative steps if a person reports symptoms that may be suggestive of lung cancer. This may reveal an obvious mass, the widening of the mediastinum (suggestive of spread to lymph nodes there), atelectasis (lung collapse), consolidation (pneumonia), or pleural effusion.[3] CT imaging is typically used to provide more information about the type and extent of disease. Bronchoscopic or CT-guided biopsy is often used to sample the tumor for histopathology.[14] Lung cancer often appears as a solitary pulmonary nodule on a chest radiograph. However, the differential diagnosis is wide. Many other diseases can also give this appearance, including metastatic cancer, hamartomas, and infectious granulomas caused by tuberculosis, histoplasmosis or coccidioidomycosis.[57] Lung cancer can also be an incidental finding, as a solitary pulmonary nodule on a chest radiograph or CT scan done for an unrelated reason.[58] The definitive diagnosis of lung cancer is based on the histological examination of the suspicious tissue[7] in the context of the clinical and radiological features.[13] Clinical practice guidelines recommend frequencies for pulmonary nodule surveillance.[59] CT imaging should not be used for longer or more frequently than indicated, as the extended surveillance exposes people to increased radiation and is costly.[59]Classification
Lung cancers are classified according to histological type.[13] This classification is important for determining both the management and predicting outcomes of the disease. Lung cancers are carcinomas – malignancies that arise from epithelial cells. Lung carcinomas are categorized by the size and appearance of the malignant cells seen by a histopathologist under a microscope. For therapeutic purposes, two broad classes are distinguished: non-small-cell lung carcinoma and small-cell lung carcinoma.[115] Non-small-cell lung carcinomaThe three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma.[7] Nearly 40% of lung cancers are adenocarcinoma, which usually comes from peripheral lung tissue.[13] Although most cases of adenocarcinoma are associated with smoking, adenocarcinoma is also the most-common form of lung cancer among people who have smoked fewer than 100 cigarettes in their lifetimes ("never-smokers")[7][61] and ex-smokers with a modest smoking history.[7] A subtype of adenocarcinoma, the bronchioloalveolar carcinoma, is more common in female never-smokers, and may have a better long-term survival.[121] Squamous-cell carcinoma causes about 30% of lung cancers. They typically occur close to large airways. A hollow cavity and associated cell death are commonly found at the center of the tumor.[13] Nearly 9% of lung cancers are large-cell carcinoma. These are so named because the cancer cells are large, with excess cytoplasm, large nuclei, and conspicuous nucleoli.[13] Small-cell lung carcinomaIn SCLC, the cells contain dense neurosecretory granules (vesicles containing neuroendocrine hormones), which give this tumor an endocrine or paraneoplastic syndrome association.[124] Most cases arise in the larger airways (primary and secondary bronchi).[14] Sixty to seventy percent have extensive disease (which cannot be targeted within a single radiation therapy field) at presentation.[7] OthersFour main histological subtypes are recognised, although some cancers may contain a combination of different subtypes,[62] such as adenosquamous carcinoma.[13] Rare subtypes include carcinoid tumors, bronchial gland carcinomas, and sarcomatoid carcinomas.[13] Metastasis
The lungs are a common place for the spread of tumors from other parts of the body. Secondary cancers are classified by the site of origin; for example, breast cancer that has been spread to the lung is called metastatic breast cancer. Metastases often have a characteristic round appearance on chest radiograph.[131] Primary lung cancers also most commonly metastasize to the brain, bones, liver, and adrenal glands.[13] Immunostaining of a biopsy usually helps determine the original source.[63] The presence of Napsin-A, TTF-1, CK7, and CK20 help confirm the subtype of lung carcinoma. SCLC that originates from neuroendocrine cells may express CD56, neural cell adhesion molecule, synaptophysin, or chromogranin.[7] Staging{{see also|Lung cancer staging}}Lung cancer staging is an assessment of the degree of spread of the cancer from its original source.[64] It is one of the factors affecting both the prognosis and the potential treatment of lung cancer.[7][64] The evaluation of non-small-cell lung carcinoma (NSCLC) staging uses the TNM classification (tumor, node, metastasis). This is based on the size of the primary tumor, lymph node involvement, and distant metastasis.[7]
Using the TNM descriptors, a group is assigned, ranging from occult cancer, through stages 0, IA (one-A), IB, IIA, IIB, IIIA, IIIB, and IV (four). This stage group assists with the choice of treatment and estimation of prognosis.[67]
SCLC has traditionally been classified as "limited stage" (confined to one-half of the chest and within the scope of a single tolerable radiotherapy field) or "extensive stage" (more widespread disease).[7] However, the TNM classification and grouping are useful in estimating prognosis.[67] For both NSCLC and SCLC, the two general types of staging evaluations are clinical staging and surgical staging. Clinical staging is performed before definitive surgery. It is based on the results of imaging studies (such as CT scans and PET scans) and biopsy results. Surgical staging is evaluated either during or after the operation. It is based on the combined results of surgical and clinical findings, including surgical sampling of thoracic lymph nodes.[13] PreventionSmoking prevention and smoking cessation are effective ways of preventing the development of lung cancer.[68]Smoking ban{{see also|Smoking ban}}While in most countries industrial and domestic carcinogens have been identified and banned, tobacco smoking is still widespread. Eliminating tobacco smoking is a primary goal in the prevention of lung cancer, and smoking cessation is an important preventive tool in this process.[69] Policy interventions to decrease passive smoking in public areas such as restaurants and workplaces have become more common in many Western countries.[70] Bhutan has had a complete smoking ban since 2005[149] while India introduced a ban on smoking in public in October 2008.[71] The World Health Organization has called for governments to institute a total ban on tobacco advertising to prevent young people from taking up smoking. They assess that such bans have reduced tobacco consumption by 16% where instituted.[72] Screening{{main|Lung cancer screening}}Cancer screening uses medical tests to detect disease in large groups of people who have no symptoms.[73] For individuals with high risk of developing lung cancer, computed tomography (CT) screening can detect cancer and give a person options to respond to it in a way that prolongs life.[59][74] This form of screening reduces the chance of death from lung cancer by an absolute amount of 0.3% (relative amount of 20%).[75][76] High risk people are those age 55–74 who have smoked equivalent amount of a pack of cigarettes daily for 30 years including time within the past 15 years.[59]CT screening is associated with a high rate of falsely positive tests which may result in unneeded treatment.[77] For each true positive scan there are about 19 falsely positives scans.[78] Other concerns include radiation exposure[77] and the cost of testing along with follow up.[59] Research has not found two other available tests—sputum cytology or chest radiograph (CXR) screening tests—to have any benefit.[74][79] The United States Preventive Services Task Force (USPSTF) recommends yearly screening using low-dose computed tomography in those who have a total smoking history of 30 pack-years and are between 55 and 80 years old until a person has not been smoking for more than 15 years.[164] Screening should not be done in those with other health problems that would make treatment of lung cancer if found not an option.[80] The English National Health Service was in 2014 re-examining the evidence for screening.[81] Other prevention strategiesThe long-term use of supplemental vitamin A,[82][83] vitamin C,[82] vitamin D[84] or vitamin E[82] does not reduce the risk of lung cancer. Some studies suggest that people who eat diets with a higher proportion of vegetables and fruit tend to have a lower risk,[26][85] but this may be due to confounding—with the lower risk actually due to the association of a high fruit and vegetables diet with less smoking.[86] Several rigorous studies have not demonstrated a clear association between diet and lung cancer risk,[7][85] although meta-analysis that accounts for smoking status may show benefit from a healthy diet.[87] Management{{main|Treatment of lung cancer}}Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the person's performance status. Common treatments include palliative care,[88] surgery, chemotherapy, and radiation therapy.[7] Targeted therapy of lung cancer is growing in importance for advanced lung cancer. Surgery{{main|Lung cancer surgery}}If investigations confirm NSCLC, the stage is assessed to determine whether the disease is localized and amenable to surgery or if it has spread to the point where it cannot be cured surgically. CT scan and positron emission tomography are used for this determination.[7] If mediastinal lymph node involvement is suspected, the nodes may be sampled to assist staging. Techniques used for this include transthoracic needle aspiration, transbronchial needle aspiration (with or without endobronchial ultrasound), endoscopic ultrasound with needle aspiration, mediastinoscopy, and thoracoscopy.[89] Blood tests and pulmonary function testing are used to assess whether a person is well enough for surgery.[14] If pulmonary function tests reveal poor respiratory reserve, surgery may not be possible.[7] In most cases of early-stage NSCLC, removal of a lobe of lung (lobectomy) is the surgical treatment of choice. In people who are unfit for a full lobectomy, a smaller sublobar excision (wedge resection) may be performed. However, wedge resection has a higher risk of recurrence than lobectomy. Radioactive iodine brachytherapy at the margins of wedge excision may reduce the risk of recurrence. Rarely, removal of a whole lung (pneumonectomy) is performed.[90] Video-assisted thoracoscopic surgery (VATS) and VATS lobectomy use a minimally invasive approach to lung cancer surgery.[91] VATS lobectomy is equally effective compared to conventional open lobectomy, with less postoperative illness.[92] In SCLC, chemotherapy and/or radiotherapy is typically used.[93] However the role of surgery in SCLC is being reconsidered. Surgery might improve outcomes when added to chemotherapy and radiation in early stage SCLC.[94] RadiotherapyRadiotherapy is often given together with chemotherapy, and may be used with curative intent in people with NSCLC who are not eligible for surgery. This form of high-intensity radiotherapy is called radical radiotherapy.[189] A refinement of this technique is continuous hyperfractionated accelerated radiotherapy (CHART), in which a high dose of radiotherapy is given in a short time period.[95] Postoperative (adjuvant) thoracic radiotherapy generally should not be used after curative-intent surgery for NSCLC.[191] Some people with mediastinal N2 lymph node involvement might benefit from post-operative radiotherapy.[96]For potentially curable SCLC cases, chest radiotherapy is often recommended in addition to chemotherapy.[13] If cancer growth blocks a short section of bronchus, brachytherapy (localized radiotherapy) may be given directly inside the airway to open the passage. Compared to external beam radiotherapy, brachytherapy allows a reduction in treatment time and reduced radiation exposure to healthcare staff.[97] Evidence for brachytherapy, however, is less than that for external beam radiotherapy.[98] Prophylactic cranial irradiation (PCI) is a type of radiotherapy to the brain, used to reduce the risk of metastasis. PCI is most useful in SCLC. In limited-stage disease, PCI increases three-year survival from 15% to 20%; in extensive disease, one-year survival increases from 13% to 27%.[99]Recent improvements in targeting and imaging have led to the development of stereotactic radiation in the treatment of early-stage lung cancer. In this form of radiotherapy, high doses are delivered over a number of sessions using stereotactic targeting techniques. Its use is primarily in patients who are not surgical candidates due to medical comorbidities.[100] For both NSCLC and SCLC patients, smaller doses of radiation to the chest may be used for symptom control (palliative radiotherapy).[101] ChemotherapyThe chemotherapy regimen depends on the tumor type.[13] SCLC, even relatively early stage disease, is treated primarily with chemotherapy and radiation.[102] In SCLC, cisplatin and etoposide are most commonly used.[201] Combinations with carboplatin, gemcitabine, paclitaxel, vinorelbine, topotecan, and irinotecan are also used.[202][203] In advanced NSCLC, chemotherapy improves survival and is used as first-line treatment, provided the person is well enough for the treatment.[204] Typically, two drugs are used, of which one is often platinum-based (either cisplatin or carboplatin). Other commonly used drugs are gemcitabine, paclitaxel, docetaxel,[103][206] pemetrexed,[104] etoposide or vinorelbine.[206] Platinum-based drugs and combinations that include platinum therapy may lead to a higher risk of serious adverse effects in people over 70 years old.[105] Adjuvant chemotherapy refers to the use of chemotherapy after apparently curative surgery to improve the outcome. In NSCLC, samples are taken of nearby lymph nodes during surgery to assist staging. If stage II or III disease is confirmed, adjuvant chemotherapy (including or not including postoperative radiotherapy) improves survival by 4% at five years.[106][107][108] The combination of vinorelbine and cisplatin is more effective than older regimens.[107] Adjuvant chemotherapy for people with stage IB cancer is controversial, as clinical trials have not clearly demonstrated a survival benefit.[109] Chemotherapy before surgery in NSCLC that can be removed surgically may improve outcomes.[110][111]Chemotherapy may be combined with palliative care in the treatment of the NSCLC. In advanced cases, appropriate chemotherapy improves average survival over supportive care alone, as well as improving quality of life.[112] With adequate physical fitness maintaining chemotherapy during lung cancer palliation offers 1.5 to 3 months of prolongation of survival, symptomatic relief, and an improvement in quality of life, with better results seen with modern agents.[113][114] The NSCLC Meta-Analyses Collaborative Group recommends if the recipient wants and can tolerate treatment, then chemotherapy should be considered in advanced NSCLC.[115][116] Targeted therapySeveral drugs that target molecular pathways in lung cancer are available, especially for the treatment of advanced disease. Erlotinib, gefitinib and afatinib inhibit tyrosine kinase at the epidermal growth factor receptor. Denosumab is a monoclonal antibody directed against receptor activator of nuclear factor kappa-B ligand. It may be useful in the treatment of bone metastases.[117] BronchoscopySeveral treatments can be administered via bronchoscopy for the management of airway obstruction or bleeding. If an airway becomes obstructed by cancer growth, options include rigid bronchoscopy, balloon bronchoplasty, stenting, and microdebridement.[118] Laser photosection involves the delivery of laser light inside the airway via a bronchoscope to remove the obstructing tumor.[119] Palliative carePalliative care when added to usual cancer care benefits people even when they are still receiving chemotherapy.[120] These approaches allow additional discussion of treatment options and provide opportunities to arrive at well-considered decisions.[121][122] Palliative care may avoid unhelpful but expensive care not only at the end of life, but also throughout the course of the illness. For individuals who have more advanced disease, hospice care may also be appropriate.[14][122]Prognosis
Of all people with lung cancer in the US, 16.8% survive for at least five years after diagnosis.[19][123] In England and Wales, between 2010 and 2011, overall five-year survival for lung cancer was estimated at 9.5%.[124] Outcomes are generally worse in the developing world.[20] Stage is often advanced at the time of diagnosis. At presentation, 30–40% of cases of NSCLC are stage IV, and 60% of SCLC are stage IV.[13] Survival for lung cancer falls as the stage at diagnosis becomes more advanced: the English data suggest that around 70% of patients survive at least a year when diagnosed at the earliest stage, but this falls to just 14% for those diagnosed with the most advanced disease (stage IV).[125] Prognostic factors in NSCLC include presence of pulmonary symptoms, large tumor size (>3 cm), non-squamous cell type (histology), degree of spread (stage) and metastases to multiple lymph nodes, and vascular invasion. For people with inoperable disease, outcomes are worse in those with poor performance status and weight loss of more than 10%.[126] Prognostic factors in small cell lung cancer include performance status, biological sex, stage of disease, and involvement of the central nervous system or liver at the time of diagnosis.[238] For NSCLC, the best prognosis is achieved with complete surgical resection of stage IA disease, with up to 70% five-year survival.[127] People with extensive-stage SCLC have an average five-year survival rate of less than 1%. The average survival time for limited-stage disease is 20 months, with a five-year survival rate of 20%.[3] According to data provided by the National Cancer Institute, the median age at diagnosis of lung cancer in the US is 70 years,[128] and the median age at death is 72 years.[129] In the US, people with medical insurance are more likely to have a better outcome.[130] EpidemiologyWorldwide, lung cancer is the most-common cancer among men in terms of both incidence and mortality, and among women has the third-highest incidence, and is second after breast cancer in mortality. In 2012, there were 1.82 million new cases worldwide, and 1.56 million deaths due to lung cancer, representing 19.4% of all deaths from cancer.[18] The highest rates are in North America, Europe, and East Asia, with over a third of new cases in China that year. Rates in Africa and South Asia are much lower.[131] The population segment that is most likely to develop lung cancer is people aged over 50 who have a history of smoking. Unlike the mortality rate in men – which began declining more than 20 years ago, women's lung cancer mortality rates have risen over the last decades, and are just recently beginning to stabilize.[246] In the US, the lifetime risk of developing lung cancer is 8% in men and 6% in women.[7] For every 3–4 million cigarettes smoked, one lung cancer death can occur.[132] The influence of "Big Tobacco" plays a significant role in smoking.[249] Young nonsmokers who see tobacco advertisements are more likely to smoke.[133] The role of passive smoking is increasingly being recognized as a risk factor for lung cancer,[29] resulting in policy interventions to decrease the undesired exposure of nonsmokers to others' tobacco smoke.[134] In the US, both black men and black women have a higher incidence.[135] Lung cancer rates are currently lower in developing countries.[254] With increased smoking in developing countries, the rates are expected to increase in the next few years, notably in both China[136] and India.[256] Also in the US, military veterans have a 25–50% higher rate of lung cancer primarily due to higher rates of smoking.[137] During World War II and the Korean War, asbestos also played a role, and Agent Orange may have caused some problems during the Vietnam War.[138] Lung cancer is the third most-common cancer in the UK (around 46,400 people were diagnosed with the disease in 2014),[139] and it is the most common cause of cancer-related death (around 35,900 people died in 2014).[140] From the 1960s, the rates of lung adenocarcinoma started to rise in relation to other kinds of lung cancer, partially due to the introduction of filter cigarettes. The use of filters removes larger particles from tobacco smoke, thus reducing deposition in larger airways. However, the smoker has to inhale more deeply to receive the same amount of nicotine, increasing particle deposition in small airways where adenocarcinoma tends to arise.[261] The incidence of lung adenocarcinoma continue to rise.[141] History{{see also|Timeline of lung cancer}}Lung cancer was uncommon before the advent of cigarette smoking; it was not even recognized as a distinct disease until 1761.[263] Different aspects of lung cancer were described further in 1810.[264] Malignant lung tumors made up only 1% of all cancers seen at autopsy in 1878, but had risen to 10–15% by the early 1900s.[265] Case reports in the medical literature numbered only 374 worldwide in 1912,[266] but a review of autopsies showed the incidence of lung cancer had increased from 0.3% in 1852 to 5.66% in 1952.[267] In Germany in 1929, physician Fritz Lickint recognized the link between smoking and lung cancer,[265] which led to an aggressive antismoking campaign.[269] The British Doctors' Study, published in the 1950s, was the first solid epidemiological evidence of the link between lung cancer and smoking.[270] As a result, in 1964 the Surgeon General of the United States recommended smokers should stop smoking.[271] The connection with radon gas was first recognized among miners in the Ore Mountains near Schneeberg, Saxony. Silver has been mined there since 1470, and these mines are rich in uranium, with its accompanying radium and radon gas.[272] Miners developed a disproportionate amount of lung disease, eventually recognized as lung cancer in the 1870s.[142] Despite this discovery, mining continued into the 1950s, due to the USSR's demand for uranium.[272] Radon was confirmed as a cause of lung cancer in the 1960s.[143] The first successful pneumonectomy for lung cancer was performed in 1933.[276] Palliative radiotherapy has been used since the 1940s.[277] Radical radiotherapy, initially used in the 1950s, was an attempt to use larger radiation doses in patients with relatively early-stage lung cancer, but who were otherwise unfit for surgery.[278] In 1997, CHART was seen as an improvement over conventional radical radiotherapy.[279] With SCLC, initial attempts in the 1960s at surgical resection[280] and radical radiotherapy[281] were unsuccessful. In the 1970s, successful chemotherapy regimens were developed.[282] Research directionsCurrent research directions for lung cancer treatment include immunotherapy,[144][145] which encourages the body's immune system to attack the tumor cells, epigenetics, and new combinations of chemotherapy and radiotherapy, both on their own and together. Many of these new treatments work through immune checkpoint blockade, disrupting cancer's ability to evade the immune system.[144][145] Ipilimumab blocks signaling through a receptor on T cells known as CTLA-4 which dampens down the immune system. It has been approved by the US Food and Drug Administration (FDA) for treatment of melanoma and is undergoing clinical trials for both NSCLC and SCLC.[144]Other immunotherapy treatments interfere with the binding of programmed cell death 1 (PD-1) protein with its ligand PD-1 ligand 1 (PD-L1), and have been approved as first- and subsequent-line treatments for various subsets of lung cancers.[145] Signaling through PD-1 inactivates T cells. Some cancer cells appear to exploit this by expressing PD-L1 in order to switch off T cells that might recognise them as a threat. Monoclonal antibodies targeting both PD-1 and PD-L1, such as pembrolizumab, nivolumab,[56] atezolizumab, and durvalumab[145] are currently in clinical trials for treatment for lung cancer.[144][145] Epigenetics is the study of small, usually heritable, molecular modifications—or "tags"—that bind to DNA and modify gene expression levels. Targeting these tags with drugs can kill cancer cells. Early-stage research in NSCLC using drugs aimed at epigenetic modifications shows that blocking more than one of these tags can kill cancer cells with fewer side effects.[146] Studies also show that giving patients these drugs before standard treatment can improve its effectiveness. Clinical trials are underway to evaluate how well these drugs kill lung cancer cells in humans.[146] Several drugs that target epigenetic mechanisms are in development. Histone deacetylase inhibitors in development include valproic acid, vorinostat, belinostat, panobinostat, entinostat, and romidepsin. DNA methyltransferase inhibitors in development include decitabine, azacytidine, and hydralazine.[52] The TRACERx project is looking at how NSCLC develops and evolves, and how these tumors become resistant to treatment.[147] The project will look at tumor samples from 850 NSCLC patients at various stages including diagnosis, after first treatment, post-treatment, and relapse.[148] By studying samples at different points of tumor development, the researchers hope to identify the changes that drive tumor growth and resistance to treatment. The results of this project will help scientists and doctors gain a better understanding of NSCLC and potentially lead to the development of new treatments for the disease.[147] For lung cancer cases that develop resistance to epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors, new drugs are in development. New EGFR inhibitors include afatinib and dacomitinib. An alternative signaling pathway, c-Met, can be inhibited by tivantinib and onartuzumab. New ALK inhibitors include crizotinib and ceritinib.[149] If the MAPK/ERK pathway is involved, the BRAF kinase inhibitor dabrafenib and the MAPK/MEK inhibitor trametinib may be beneficial.[150] Lung cancer stem cells are often resistant to conventional chemotherapy and radiotherapy. This may lead to relapse after treatment. New approaches target protein or glycoprotein markers that are specific to the stem cells. Such markers include CD133, CD90, ALDH1A1, CD44 and ABCG2. Signaling pathways such as Hedgehog, Wnt and Notch are often implicated in the self-renewal of stem cell lines. Thus treatments targeting these pathways may help to prevent relapse.[151] References{{Clear}}1. ^{{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}} [152][153][154][155][156][157][158][159][160][161][162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180][181][182][183][184][185][186][187][188][189]2. ^{{cite journal|last1=GBD 2015 Mortality and Causes of Death|first1=Collaborators.|title=Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1459–1544|pmid=27733281|doi=10.1016/S0140-6736(16)31012-1|pmc=5388903}} 3. ^1 2 3 4 5 6 7 8 {{cite web | title=Lung Carcinoma: Tumors of the Lungs | publisher=Merck Manual Professional Edition, Online edition | url=http://www.merck.com/mmpe/sec05/ch062/ch062b.html#sec05-ch062-ch062b-1405 | accessdate=15 August 2007 | deadurl=no | archiveurl=https://web.archive.org/web/20070816142739/http://www.merck.com/mmpe/sec05/ch062/ch062b.html#sec05-ch062-ch062b-1405 | archivedate=16 August 2007 | df=dmy-all }} 4. ^{{cite web|title=Non-Small Cell Lung Cancer Treatment –Patient Version (PDQ®)|url=http://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq|website=NCI|accessdate=5 March 2016|date=May 12, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20160229172247/http://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq|archivedate=29 February 2016|df=dmy-all}} 5. ^{{cite book | vauthors = Falk S, Williams C | title=Lung Cancer—the facts | edition=3rd | chapter=Chapter 1 | pages=3–4 | publisher=Oxford University Press | year=2010 | isbn=978-0-19-956933-5 }} 6. ^1 2 {{cite web|title=Lung Cancer—Patient Version|url=http://www.cancer.gov/types/lung|website=NCI|accessdate=5 March 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160309175259/http://www.cancer.gov/types/lung|archivedate=9 March 2016|df=dmy-all|date=1980-01-01}} 7. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 {{cite book | vauthors = Horn L, Lovly CM | title=Harrison's Principles of Internal Medicine | publisher=McGraw-Hill | veditors=Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J | year=2018 | chapter=Chapter 74: Neoplasms of the lung | edition=20th | isbn=978-1259644030 }} 8. ^{{Cite journal |vauthors=Thun MJ, Hannan LM, Adams-Campbell LL, etal | title=Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies | journal=PLoS Medicine | volume=5 | issue=9 | pages=e185 |date=September 2008 | doi=10.1371/journal.pmed.0050185 | pmid=18788891 | pmc=2531137 }} 9. ^1 2 3 4 5 6 7 {{cite book | vauthors = Alberg AJ, Brock MV, Samet JM | title=Murray & Nadel's Textbook of Respiratory Medicine | publisher=Saunders Elsevier | year=2016 | chapter=Chapter 52: Epidemiology of lung cancer | edition=6th | isbn=978-1-4557-3383-5 }} 10. ^1 2 {{cite journal | vauthors = O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ | title = Asbestos-related lung disease | journal = American Family Physician | volume = 75 | issue = 5 | pages = 683–8 | date = March 2007 | pmid = 17375514 | url = http://www.aafp.org/afp/20070301/683.html | archive-url = https://web.archive.org/web/20070929083111/http://www.aafp.org/afp/20070301/683.html | df = dmy-all | deadurl = no | archive-date = 29 September 2007 }} 11. ^{{cite book |url=https://www.ncbi.nlm.nih.gov/books/NBK44324/ | vauthors = Carmona RH |publisher=U.S. Department of Health and Human Services |title=The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General |date=27 June 2006 |quote=Secondhand smoke exposure causes disease and premature death in children and adults who do not smoke. |deadurl=no |archiveurl=https://web.archive.org/web/20170215064658/https://www.ncbi.nlm.nih.gov/books/NBK44324/ |archivedate=15 February 2017 |df=dmy-all | series = Publications and Reports of the Surgeon General }} Retrieved 2014-06-16 12. ^{{Cite journal |url=http://monographs.iarc.fr/ENG/Monographs/vol83/mono83.pdf |publisher=WHO International Agency for Research on Cancer |title=Tobacco Smoke and Involuntary Smoking |journal=IARC Monographs on the Evaluation of Carcinogenic Risks to Humans |volume=83 |year=2004 |quote=There is sufficient evidence that involuntary smoking (exposure to secondhand or 'environmental' tobacco smoke) causes lung cancer in humans. ... Involuntary smoking (exposure to secondhand or 'environmental' tobacco smoke) is carcinogenic to humans (Group 1). |deadurl=no |archiveurl=https://web.archive.org/web/20150813204458/http://monographs.iarc.fr/ENG/Monographs/vol83/mono83.pdf |archivedate=13 August 2015 |df=dmy-all }} 13. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 {{cite book | vauthors=Lu C, Onn A, Vaporciyan AA, etal | title=Holland-Frei Cancer Medicine | edition=8th | chapter=Chapter 78: Cancer of the Lung | publisher=People's Medical Publishing House | year=2010 |isbn=978-1-60795-014-1 }} 14. ^1 2 3 4 5 {{cite journal | vauthors = Collins LG, Haines C, Perkel R, Enck RE | title = Lung cancer: diagnosis and management | journal = American Family Physician | volume = 75 | issue = 1 | pages = 56–63 | date = January 2007 | pmid = 17225705 | url = http://www.aafp.org/afp/20070101/56.html | archive-url = https://web.archive.org/web/20070929104510/http://www.aafp.org/afp/20070101/56.html | df = dmy-all | deadurl = no | archive-date = 29 September 2007 }} 15. ^{{cite web|title=Lung Cancer Prevention–Patient Version (PDQ®)|url=http://www.cancer.gov/types/lung/patient/lung-prevention-pdq#section/_12|website=NCI|accessdate=5 March 2016|date=November 4, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20160309063009/http://www.cancer.gov/types/lung/patient/lung-prevention-pdq#section/_12|archivedate=9 March 2016|df=dmy-all}} 16. ^{{cite book | vauthors = Chapman S, Robinson G, Stradling J, West S, Wrightson J | title=Oxford Handbook of Respiratory Medicine | edition=3rd | chapter=Chapter 31 | page=284 | publisher=Oxford University Press | year=2014 | isbn=978-0-19-870386-0 }} 17. ^1 {{cite book|title=World Cancer Report 2014|date=2014|publisher=World Health Organization|isbn=978-92-832-0429-9|pages=Chapter 5.1}} 18. ^1 {{cite book|title=World Cancer Report 2014|date=2014|publisher=World Health Organization|isbn=978-92-832-0429-9|pages=Chapter 1.1}} 19. ^1 2 3 4 {{cite web | title=Surveillance, Epidemiology and End Results Program | url=http://seer.cancer.gov/statfacts/html/lungb.html | website=National Cancer Institute | accessdate=5 Mar 2016 | deadurl=no | archiveurl=https://web.archive.org/web/20160304031945/http://seer.cancer.gov/statfacts/html/lungb.html | archivedate=4 March 2016 | df=dmy-all }} 20. ^1 {{cite book|last=Majumder|first=Sadhan | name-list-format = vanc |title=Stem cells and cancer|year=2009|publisher=Springer|location=New York|isbn=978-0-387-89611-3|page=193|url=https://books.google.com/books?id=HaErOupWnO0C&pg=PA193|edition=Online-Ausg.|deadurl=no|archiveurl=https://web.archive.org/web/20151018040051/https://books.google.com/books?id=HaErOupWnO0C&pg=PA193|archivedate=18 October 2015|df=dmy-all}} 21. ^{{Cite book |vauthors=Brown KM, Keats JJ, Sekulic A, et al. | title=Holland-Frei Cancer Medicine | publisher=People's Medical Publishing House USA | year=2010 | chapter=Chapter 8 | edition=8th | isbn=978-1-60795-014-1 }} 22. ^1 {{Cite journal | vauthors = Hecht SS | title=Lung carcinogenesis by tobacco smoke |journal=International Journal of Cancer | volume=131 | issue=12 | pages=2724–2732 | year=2012 | pmid=22945513 | doi=10.1002/ijc.27816 | pmc=3479369 }} 23. ^{{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=199 | chapter=Chapter 5 | isbn=978-1-4377-1781-5 }} 24. ^{{cite journal | vauthors = | title = Health effects of exposure to environmental tobacco smoke. California Environmental Protection Agency | journal = Tobacco Control | volume = 6 | issue = 4 | pages = 346–53 | year = 1997 | pmid = 9583639 | pmc = 1759599 | doi = 10.1136/tc.6.4.346 | url = http://www.druglibrary.org/schaffer/tobacco/caets/ets-main.htm | archive-url = https://web.archive.org/web/20070808045344/http://druglibrary.org/schaffer/tobacco/caets/ets-main.htm | df = dmy-all | deadurl = no | archive-date = 8 August 2007 }} 25. ^{{cite journal | title = State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke—United States, 2000 | journal = MMWR. Morbidity and Mortality Weekly Report | volume = 50 | issue = 49 | pages = 1101–6 | date = December 2001 | pmid = 11794619 | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5049a1.htm | authorlink = Centers for Disease Control and Prevention | archive-url = https://web.archive.org/web/20170625143734/https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5049a1.htm | df = dmy-all | deadurl = no | archive-date = 25 June 2017 | author1 = Centers for Disease Control Prevention (CDC) }} 26. ^1 2 {{cite journal | vauthors = Alberg AJ, Ford JG, Samet JM | title = Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) | journal = Chest | volume = 132 | issue = 3 Suppl | pages = 29S–55S | date = September 2007 | pmid = 17873159 | doi = 10.1378/chest.07-1347 | url = http://chestjournal.chestpubs.org/content/132/3_suppl/29S.long }} 27. ^{{cite journal | vauthors = Jaakkola MS, Jaakkola JJ | title = Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention | journal = The European Respiratory Journal | volume = 28 | issue = 2 | pages = 397–408 | date = August 2006 | pmid = 16880370 | doi = 10.1183/09031936.06.00001306 | df = dmy-all }} 28. ^{{cite journal | vauthors = Parkin DM | title = 2. Tobacco-attributable cancer burden in the UK in 2010 | journal = British Journal of Cancer | volume = 105 Suppl 2 | issue = Suppl. 2 | pages = S6–S13 | date = December 2011 | pmid = 22158323 | pmc = 3252064 | doi = 10.1038/bjc.2011.475 }} 29. ^1 {{cite journal | vauthors = Taylor R, Najafi F, Dobson A | title = Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent | journal = International Journal of Epidemiology | volume = 36 | issue = 5 | pages = 1048–59 | date = October 2007 | pmid = 17690135 | doi = 10.1093/ije/dym158 | url = http://ije.oxfordjournals.org/content/36/5/1048.long | archive-url = https://web.archive.org/web/20110805173006/http://ije.oxfordjournals.org/content/36/5/1048.long | df = dmy-all | deadurl = no | archive-date = 5 August 2011 }} 30. ^{{cite web|title=Frequently asked questions about second hand smoke|url=http://www.who.int/tobacco/research/secondhand_smoke/faq/en/index.html|work=World Health Organization|access-date=25 July 2012|deadurl=no|archive-url=https://web.archive.org/web/20130101163934/http://www.who.int/tobacco/research/secondhand_smoke/faq/en/index.html|archive-date=1 January 2013|df=dmy-all}} 31. ^{{cite journal | vauthors = Greydanus DE, Hawver EK, Greydanus MM, Merrick J | title = Marijuana: current concepts(†) | journal = Frontiers in Public Health | volume = 1 | issue = 42 | pages = 42 | date = October 2013 | pmid = 24350211 | pmc = 3859982 | doi = 10.3389/fpubh.2013.00042 }} 32. ^{{cite journal | vauthors = Owen KP, Sutter ME, Albertson TE | title = Marijuana: respiratory tract effects | journal = Clinical Reviews in Allergy & Immunology | volume = 46 | issue = 1 | pages = 65–81 | date = February 2014 | pmid = 23715638 | doi = 10.1007/s12016-013-8374-y }} 33. ^{{cite journal | vauthors = Joshi M, Joshi A, Bartter T | title = Marijuana and lung diseases | journal = Current Opinion in Pulmonary Medicine | volume = 20 | issue = 2 | pages = 173–9 | date = March 2014 | pmid = 24384575 | doi = 10.1097/mcp.0000000000000026 }} 34. ^{{cite journal | vauthors = Tashkin DP | title = Effects of marijuana smoking on the lung | journal = Annals of the American Thoracic Society | volume = 10 | issue = 3 | pages = 239–47 | date = June 2013 | pmid = 23802821 | doi = 10.1513/annalsats.201212-127fr }} 35. ^{{cite journal | vauthors = Underner M, Urban T, Perriot J, de Chazeron I, Meurice JC | title = [Cannabis smoking and lung cancer] | journal = Revue des Maladies Respiratoires | volume = 31 | issue = 6 | pages = 488–98 | date = June 2014 | pmid = 25012035 | doi = 10.1016/j.rmr.2013.12.002 }} 36. ^{{cite journal | vauthors = Choi H, Mazzone P | title = Radon and lung cancer: assessing and mitigating the risk | journal = Cleveland Clinic Journal of Medicine | volume = 81 | issue = 9 | pages = 567–75 | date = September 2014 | pmid = 25183848 | doi = 10.3949/ccjm.81a.14046 | url = http://www.ccjm.org/content/81/9/567.long }} 37. ^{{cite web | title=Radon (Rn) Health Risks | publisher=EPA | url=http://www.epa.gov/radon/healthrisks.html | deadurl=no | archiveurl=https://web.archive.org/web/20081020231845/http://www.epa.gov/radon/healthrisks.html | archivedate=20 October 2008 | df=dmy-all | date=2013-08-27 }} 38. ^{{cite journal |vauthors=Schmid K, Kuwert T, Drexler H | title=Radon in Indoor Spaces: An Underestimated Risk Factor for Lung Cancer in Environmental Medicine | journal=Dtsch Arztebl Int | volume=107 | issue=11 | pages=181–6 | date=March 2010 | pmid=20386676 | pmc=2853156 | doi=10.3238/arztebl.2010.0181 | url= }} 39. ^{{cite book | vauthors = Tobias J, Hochhauser D | title=Cancer and its Management | publisher=Wiley-Blackwell | year=2010 | page=199 | chapter=Chapter 12 | edition=6th | isbn=978-1-4051-7015-4 }} 40. ^{{cite book | vauthors = Davies RJ, Lee YC | title=Oxford Textbook Medicine | publisher=OUP Oxford | year=2010 | chapter=18.19.3 | edition=5th | isbn=978-0-19-920485-4 }} 41. ^{{cite journal | vauthors = Chen H, Goldberg MS, Villeneuve PJ | title = A systematic review of the relation between long-term exposure to ambient air pollution and chronic diseases | journal = Reviews on Environmental Health | volume = 23 | issue = 4 | pages = 243–97 | date = Oct–Dec 2008 | pmid = 19235364 | doi = 10.1515/reveh.2008.23.4.243 }} 42. ^{{cite journal | vauthors = Clapp RW, Jacobs MM, Loechler EL | title = Environmental and occupational causes of cancer: new evidence 2005–2007 | journal = Reviews on Environmental Health | volume = 23 | issue = 1 | pages = 1–37 | date = Jan–Mar 2008 | pmid = 18557596 | pmc = 2791455 | doi = 10.1515/REVEH.2008.23.1.1 }} 43. ^1 {{cite journal | vauthors = Lim WY, Seow A | title = Biomass fuels and lung cancer | journal = Respirology | volume = 17 | issue = 1 | pages = 20–31 | date = January 2012 | pmid = 22008241 | doi = 10.1111/j.1440-1843.2011.02088.x }} 44. ^1 {{cite journal | vauthors = Sood A | title = Indoor fuel exposure and the lung in both developing and developed countries: an update | journal = Clinics in Chest Medicine | volume = 33 | issue = 4 | pages = 649–65 | date = December 2012 | pmid = 23153607 | pmc = 3500516 | doi = 10.1016/j.ccm.2012.08.003 }} 45. ^{{cite journal | vauthors = Yang IA, Holloway JW, Fong KM | title = Genetic susceptibility to lung cancer and co-morbidities | journal = Journal of Thoracic Disease | volume = 5 Suppl 5 | issue = Suppl. 5 | pages = S454–62 | date = October 2013 | pmid = 24163739 | pmc = 3804872 | doi = 10.3978/j.issn.2072-1439.2013.08.06 }} 46. ^{{Cite book | vauthors = Dela Cruz CS, Tanoue LT, Matthay RA | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill | veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 109: Epidemiology of lung cancer | page=1673 | edition=5th | isbn=978-0-07-179672-9 }} 47. ^1 {{cite journal | vauthors = Larsen JE, Minna JD | title = Molecular biology of lung cancer: clinical implications | journal = Clinics in Chest Medicine | volume = 32 | issue = 4 | pages = 703–40 | date = December 2011 | pmid = 22054881 | pmc = 3367865 | doi = 10.1016/j.ccm.2011.08.003 }} 48. ^{{cite journal | vauthors = Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP | display-authors = 6 | title = Preventable exposures associated with human cancers | journal = Journal of the National Cancer Institute | volume = 103 | issue = 24 | pages = 1827–39 | date = December 2011 | pmid = 22158127 | pmc = 3243677 | doi = 10.1093/jnci/djr483 | url = http://monographs.iarc.fr/ENG/Classification/Table4.pdf | archive-url = https://web.archive.org/web/20120920150724/http://monographs.iarc.fr/ENG/Classification/Table4.pdf | df = dmy-all | deadurl = no | archive-date = 20 September 2012 }} 49. ^{{cite journal | vauthors = Cooper WA, Lam DC, O'Toole SA, Minna JD | title = Molecular biology of lung cancer | journal = Journal of Thoracic Disease | volume = 5 Suppl 5 | issue = Suppl. 5 | pages = S479–90 | date = October 2013 | pmid = 24163741 | pmc = 3804875 | doi = 10.3978/j.issn.2072-1439.2013.08.03 }} 50. ^{{Cite book | vauthors = Tobias J, Hochhauser D | title=Cancer and its Management | publisher=Wiley-Blackwell | year=2010 | page=200 | chapter=Chapter 12 | edition=6th | isbn=978-1-4051-7015-4 }} 51. ^{{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=212 | chapter=Chapter 5 | isbn=978-1-4377-1781-5 }} 52. ^1 {{cite journal | vauthors = Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE | title = Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy | journal = Frontiers in Oncology | volume = 3 | issue = 261 | pages = 261 | date = October 2013 | pmid = 24130964 | pmc = 3793201 | doi = 10.3389/fonc.2013.00261 }} 53. ^{{cite journal | title = Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. | journal = Cancer Cell | volume = 33 | issue = 6 | pages = 985–1003 | date = June 2018 | pmid = 29805077 | pmc = 6100788 | doi = 10.1016/j.ccell.2018.05.001 | last1 = Takahashi | first1 = Nobuaki | last2 = Chen | first2 = Hsing-Yu | last3 = Harris | first3 = Isaac S. | last4 = Stover | first4 = Daniel G. | last5 = Selfors | first5 = Laura M. | last6 = Bronson | first6 = Roderick T. | last7 = Deraedt | first7 = Thomas | last8 = Cichowski | first8 = Karen | last9 = Welm | first9 = Alana L. | last10 = Mori | first10 = Yasuo | last11 = Mills | first11 = Gordon B. | last12 = Brugge | first12 = Joan S. }} 54. ^{{cite journal | title = Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. | journal = Pharmacology & Therapeutics | volume = 194 | pages = 59–72 | date = September 2018 | pmid = 30240635 | doi = 10.1016/j.pharmthera.2018.09.004 | last1 = Vlahopoulos | first1 = Spiros | last2 = Adamaki | first2 = Maria | last3 = Khoury | first3 = Nikolas | last4 = Zoumpourlis | first4 = Vassilis | last5 = Boldogh | first5 = Istvan }} 55. ^1 {{cite journal | vauthors = Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B | title = The role of stem cells in airway repair: implications for the origins of lung cancer | journal = Chinese Journal of Cancer | volume = 32 | issue = 2 | pages = 71–4 | date = February 2013 | pmid = 23114089 | pmc = 3845611 | doi = 10.5732/cjc.012.10097 }} 56. ^1 {{cite journal | vauthors = Powell CA, Halmos B, Nana-Sinkam SP | title = Update in lung cancer and mesothelioma 2012 | journal = American Journal of Respiratory and Critical Care Medicine | volume = 188 | issue = 2 | pages = 157–66 | date = July 2013 | pmid = 23855692 | pmc = 3778761 | doi = 10.1164/rccm.201304-0716UP }} 57. ^{{cite book | vauthors = Ost D | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill | veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 110: Approach to the patient with pulmonary nodules | page=1685 | edition=5th | isbn=978-0-07-179672-9 }} 58. ^{{cite journal | vauthors = Frank L, Quint LE | title = Chest CT incidentalomas: thyroid lesions, enlarged mediastinal lymph nodes, and lung nodules | journal = Cancer Imaging | volume = 12 | issue = 1 | pages = 41–8 | date = March 2012 | pmid = 22391408 | pmc = 3335330 | doi = 10.1102/1470-7330.2012.0006 }} 59. ^1 2 3 4 {{cite web |author1 = American College of Chest Physicians |author1-link = American College of Chest Physicians |author2 = American Thoracic Society |author2-link = American Thoracic Society |date = September 2013 |title = Five Things Physicians and Patients Should Question |publisher = American College of Chest Physicians and American Thoracic Society |work = Choosing Wisely: an initiative of the ABIM Foundation |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/ |access-date = 6 January 2013 |deadurl = no |archive-url = https://web.archive.org/web/20131103063427/http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/ |archive-date = 3 November 2013 |df = dmy-all }} 60. ^Smokers defined as current or former smoker of more than 1 year of duration. See image page in Commons for percentages in numbers. Reference: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044470/table/T2/ Table 2] {{webarchive|url=https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044470/table/T2/ |date=10 September 2017 }} in: {{cite journal | vauthors = Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA | title = Comparison of aspects of smoking among the four histological types of lung cancer | journal = Tobacco Control | volume = 17 | issue = 3 | pages = 198–204 | date = June 2008 | pmid = 18390646 | pmc = 3044470 | doi = 10.1136/tc.2007.022582 }} 61. ^{{cite journal | vauthors = Subramanian J, Govindan R | title = Lung cancer in never smokers: a review | journal = Journal of Clinical Oncology | volume = 25 | issue = 5 | pages = 561–70 | date = February 2007 | pmid = 17290066 | doi = 10.1200/JCO.2006.06.8015 }} 62. ^1 {{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=505 | chapter=12 | isbn=978-1-4377-1781-5 }} 63. ^{{cite journal |vauthors=Tan D, Zander DS |title=Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update |journal=Int J Clin Exp Pathol |volume=1 |issue=1 |pages=19–31 |year=2008|pmid=18784820 |pmc=2480532 }} 64. ^1 {{cite book | vauthors=Connolly JL, Goldsmith JD, Wang HH, etal | title=Holland-Frei Cancer Medicine | edition=8th | chapter=37: Principles of Cancer Pathology | publisher=People's Medical Publishing House | year=2010 |isbn=978-1-60795-014-1 }} 65. ^{{cite web | title=8th edition lung cancer TNM staging summary | publisher=International Association for the Study of Lung Cancer | url=https://www.iaslc.org/sites/default/files/wysiwyg-assets/iaslc_8th_posters_24x36_2018_final_version_1.pdf }} 66. ^{{cite journal | vauthors = Van Schil PE, Rami-Porta R, Asamura H | title = 8th TNM edition for lung cancer: a critical analysis | journal = Annals of Translational Medicine | volume = 6 | issue = 5 | pages = 87 | date = March 2018 | pmid = 29666810 | pmc = 5890051 | doi = 10.21037/atm.2017.06.45 }} 67. ^1 2 {{cite journal | vauthors = Rami-Porta R, Crowley JJ, Goldstraw P | title = The revised TNM staging system for lung cancer | journal = Annals of Thoracic and Cardiovascular Surgery | volume = 15 | issue = 1 | pages = 4–9 | date = February 2009 | pmid = 19262443 | url = http://www.atcs.jp/pdf/2009_15_1/4.pdf | archive-url = https://web.archive.org/web/20120509223416/http://www.atcs.jp/pdf/2009_15_1/4.pdf | df = dmy-all | deadurl = no | archive-date = 9 May 2012 }} 68. ^{{cite journal | vauthors = Dela Cruz CS, Tanoue LT, Matthay RA | title = Lung cancer: epidemiology, etiology, and prevention | journal = Clinics in Chest Medicine | volume = 32 | issue = 4 | pages = 605–44 | date = December 2011 | pmid = 22054876 | pmc = 3864624 | doi = 10.1016/j.ccm.2011.09.001 }} 69. ^{{cite journal | vauthors = Goodman GE | title=Lung cancer. 1: prevention of lung cancer | journal=Thorax | volume=57 | issue=11 | date=November 2002 | pages=994–999 | pmid=12403886 | pmc=1746232 | doi=10.1136/thorax.57.11.994 | df=dmy-all }} 70. ^{{cite journal | vauthors = McNabola A, Gill LW | title = The control of environmental tobacco smoke: a policy review | journal = International Journal of Environmental Research and Public Health | volume = 6 | issue = 2 | pages = 741–58 | date = February 2009 | pmid = 19440413 | pmc = 2672352 | doi = 10.3390/ijerph6020741 }} 71. ^{{cite news | vauthors = Pandey G | title=Indian ban on smoking in public | url=http://news.bbc.co.uk/1/hi/world/south_asia/7645868.stm | publisher=BBC | date=2 October 2008 | access-date=25 April 2012 | deadurl=no | archive-url=https://web.archive.org/web/20090115143617/http://news.bbc.co.uk/1/hi/world/south_asia/7645868.stm | archive-date=15 January 2009 | df=dmy-all }} 72. ^{{Cite press release |title=UN health agency calls for total ban on tobacco advertising to protect young |url=https://www.un.org/apps/news/story.asp?NewsID=26857 |publisher=United Nations News service |date=30 May 2008 |deadurl=no |archive-url=https://web.archive.org/web/20160304201703/http://www.un.org/apps/news/story.asp?NewsID=26857 |archive-date=4 March 2016 |df=dmy-all }} 73. ^{{cite journal | vauthors = Gutierrez A, Suh R, Abtin F, Genshaft S, Brown K | title = Lung cancer screening | journal = Seminars in Interventional Radiology | volume = 30 | issue = 2 | pages = 114–20 | date = June 2013 | pmid = 24436526 | pmc = 3709936 | doi = 10.1055/s-0033-1342951 }} 74. ^1 {{cite journal | vauthors = Usman Ali M, Miller J, Peirson L, Fitzpatrick-Lewis D, Kenny M, Sherifali D, Raina P | title = Screening for lung cancer: A systematic review and meta-analysis | journal = Preventive Medicine | volume = 89 | pages = 301–14 | date = August 2016 | pmid = 27130532 | doi = 10.1016/j.ypmed.2016.04.015 }} 75. ^{{cite journal |vauthors=Jaklitsch MT, Jacobson FL, Austin JH, etal | title=The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups | journal=Journal of Thoracic and Cardiovascular Surgery |date=July 2012 | volume=144 | issue=1 | pages=33–38 | pmid=22710039 | doi=10.1016/j.jtcvs.2012.05.060}} 76. ^{{cite journal |vauthors=Bach PB, Mirkin JN, Oliver TK, etal | title=Benefits and harms of CT screening for lung cancer: a systematic review | journal=JAMA: The Journal of the American Medical Association |date=June 2012 | volume=307 | issue=22 | pages=2418–2429 | pmid=22610500 | doi=10.1001/jama.2012.5521 | pmc=3709596}} 77. ^1 {{cite journal | vauthors = Aberle DR, Abtin F, Brown K | title = Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial | journal = Journal of Clinical Oncology | volume = 31 | issue = 8 | pages = 1002–8 | date = March 2013 | pmid = 23401434 | pmc = 3589698 | doi = 10.1200/JCO.2012.43.3110 }} 78. ^{{cite journal | vauthors = Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC | title = Benefits and harms of CT screening for lung cancer: a systematic review | journal = JAMA | volume = 307 | issue = 22 | pages = 2418–29 | date = June 2012 | pmid = 22610500 | pmc = 3709596 | doi = 10.1001/jama.2012.5521 }} 79. ^{{cite journal | vauthors = Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D | title = Screening for lung cancer | journal = The Cochrane Database of Systematic Reviews | volume = 6 | issue = 6 | pages = CD001991 | date = June 2013 | pmid = 23794187 | doi = 10.1002/14651858.CD001991.pub3 }} 80. ^1 {{cite journal | vauthors = Moyer VA | title = Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement | journal = Annals of Internal Medicine | volume = 160 | issue = 5 | pages = 330–8 | date = March 2014 | pmid = 24378917 | doi = 10.7326/M13-2771 }} 81. ^{{cite journal | vauthors = Baldwin DR, Hansell DM, Duffy SW, Field JK | title = Lung cancer screening with low dose computed tomography | journal = BMJ | volume = 348 | pages = g1970 | date = March 2014 | pmid = 24609921 | doi = 10.1136/bmj.g1970 }} 82. ^1 2 {{cite journal | vauthors = Fabricius P, Lange P | title = Diet and lung cancer | journal = Monaldi Archives for Chest Disease = Archivio Monaldi per le Malattie del Torace | volume = 59 | issue = 3 | pages = 207–11 | date = July–September 2003 | pmid = 15065316 }} 83. ^{{cite journal | vauthors = Fritz H, Kennedy D, Fergusson D, Fernandes R, Doucette S, Cooley K, Seely A, Sagar S, Wong R, Seely D | title = Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis | journal = PLOS One | volume = 6 | issue = 6 | pages = e21107 | year = 2011 | pmid = 21738614 | pmc = 3124481 | doi = 10.1371/journal.pone.0021107 | bibcode = 2011PLoSO...621107F }} {{open access}} 84. ^{{cite journal | vauthors = Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkina T, Branscheidt M, Eschmann R, Bals R | title = The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer | journal = Respiratory Research | volume = 12 | issue = 1 | pages = 31 | date = March 2011 | pmid = 21418564 | pmc = 3071319 | doi = 10.1186/1465-9921-12-31 }} 85. ^1 {{cite journal | vauthors = Key TJ | title = Fruit and vegetables and cancer risk | journal = British Journal of Cancer | volume = 104 | issue = 1 | pages = 6–11 | date = January 2011 | pmid = 21119663 | pmc = 3039795 | doi = 10.1038/sj.bjc.6606032 }} 86. ^{{cite journal | vauthors = Bradbury KE, Appleby PN, Key TJ | title = Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) | journal = The American Journal of Clinical Nutrition | volume = 100 Suppl 1 | issue = Suppl. 1 | pages = 394S–8S | date = July 2014 | pmid = 24920034 | doi = 10.3945/ajcn.113.071357 | df = dmy-all }} 87. ^{{cite journal | vauthors = Sun Y, Li Z, Li J, Li Z, Han J | title = A Healthy Dietary Pattern Reduces Lung Cancer Risk: A Systematic Review and Meta-Analysis | journal = Nutrients | volume = 8 | issue = 3 | pages = 134 | date = March 2016 | pmid = 26959051 | pmc = 4808863 | doi = 10.3390/nu8030134 }} 88. ^{{cite journal | vauthors = Ferrell B, Koczywas M, Grannis F, Harrington A | title = Palliative care in lung cancer | journal = The Surgical Clinics of North America | volume = 91 | issue = 2 | pages = 403–17, ix | date = April 2011 | pmid = 21419260 | pmc = 3655433 | doi = 10.1016/j.suc.2010.12.003 }} 89. ^{{cite book | vauthors = Chang L, Rivera MP | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill | veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 112: Clinical evaluation, diagnosis, and staging of lung cancer | page=1728 | edition=5th | isbn=978-0-07-179672-9 }} 90. ^{{Cite book | vauthors =Reznik SI, Smythe WR | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill | veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 113: Treatment of non-small-cell lung cancer: surgery | pages=1737–1738 | edition=5th | isbn=978-0-07-179672-9 }} 91. ^{{cite journal | vauthors = Alam N, Flores RM | title = Video-assisted thoracic surgery (VATS) lobectomy: the evidence base | journal = JSLS | volume = 11 | issue = 3 | pages = 368–74 | date = July–September 2007 | pmid = 17931521 | pmc = 3015831 }} 92. ^{{cite journal | vauthors = Rueth NM, Andrade RS | title = Is VATS lobectomy better: perioperatively, biologically and oncologically? | journal = The Annals of Thoracic Surgery | volume = 89 | issue = 6 | pages = S2107–11 | date = June 2010 | pmid = 20493991 | doi = 10.1016/j.athoracsur.2010.03.020 }} 93. ^{{cite journal | vauthors = Simon GR, Turrisi A | title = Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) | journal = Chest | volume = 132 | issue = 3 Suppl | pages = 324S–339S | date = September 2007 | pmid = 17873178 | doi = 10.1378/chest.07-1385 | url = http://chestjournal.chestpubs.org/content/132/3_suppl/324S.long }} 94. ^{{cite journal | vauthors = Goldstein SD, Yang SC | title = Role of surgery in small cell lung cancer | journal = Surgical Oncology Clinics of North America | volume = 20 | issue = 4 | pages = 769–77 | date = October 2011 | pmid = 21986271 | doi = 10.1016/j.soc.2011.08.001 }} 95. ^{{cite journal | vauthors = Hatton MQ, Martin JE | title = Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions | journal = Clinical Oncology | volume = 22 | issue = 5 | pages = 356–64 | date = June 2010 | pmid = 20399629 | doi = 10.1016/j.clon.2010.03.010 }} 96. ^{{cite journal | vauthors = Le Péchoux C | title = Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data | journal = The Oncologist | volume = 16 | issue = 5 | pages = 672–81 | year = 2011 | pmid = 21378080 | pmc = 3228187 | doi = 10.1634/theoncologist.2010-0150 }} 97. ^{{cite journal | vauthors = Ikushima H | title=Radiation therapy: state of the art and the future | journal=Journal of Medical Investigation | volume=57 | issue=1–2 | pages=1–11 | date=February 2010 | url=http://www.jstage.jst.go.jp/article/jmi/57/1,2/1/_pdf | pmid=20299738 | doi=10.2152/jmi.57.1 }}{{dead link|date=December 2017 |bot=InternetArchiveBot |fix-attempted=yes }} 98. ^{{cite journal | vauthors = Reveiz L, Rueda JR, Cardona AF | title = Palliative endobronchial brachytherapy for non-small cell lung cancer | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD004284 | date = December 2012 | pmid = 23235606 | doi = 10.1002/14651858.CD004284.pub3 }} 99. ^{{cite journal | vauthors = Paumier A, Cuenca X, Le Péchoux C | title = Prophylactic cranial irradiation in lung cancer | journal = Cancer Treatment Reviews | volume = 37 | issue = 4 | pages = 261–5 | date = June 2011 | pmid = 20934256 | doi = 10.1016/j.ctrv.2010.08.009 }} 100. ^{{cite journal | vauthors = Girard N, Mornex F | title = [Stereotactic radiotherapy for non-small cell lung cancer: From concept to clinical reality. 2011 update] | journal = Cancer/Radiothérapie | volume = 15 | issue = 6–7 | pages = 522–6 | date = October 2011 | pmid = 21889901 | doi = 10.1016/j.canrad.2011.07.241 }} 101. ^{{Cite journal | vauthors=Fairchild A, Harris K, Barnes E, etal | title=Palliative thoracic radiotherapy for lung cancer: a systematic review | journal=Journal of Clinical Oncology | volume=26 | issue=24 | pages=4001–4011 | date=August 2008 | pmid=18711191 | url=http://jco.ascopubs.org/content/26/24/4001.full | doi=10.1200/JCO.2007.15.3312 | deadurl=no | archiveurl=https://web.archive.org/web/20130413233918/http://jco.ascopubs.org/content/26/24/4001.full | archivedate=13 April 2013 | df=dmy-all }} 102. ^{{cite journal |vauthors=Hann CL, Rudin CM |title=Management of small-cell lung cancer: incremental changes but hope for the future |journal=Oncology (Williston Park)|date=30 November 2008|volume=22|issue=13|pages=1486–92 |pmid=19133604|pmc=4124612 }} 103. ^{{Cite book | vauthors = Carr LL, Jett JR | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill |veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 114: Treatment of non-small-cell lung cancer: chemotherapy | page=1752 | edition=5th | isbn=978-0-07-179672-9 }} 104. ^{{cite journal |vauthors=Fuld AD, Dragnev KH, Rigas JR |title=Pemetrexed in advanced non-small-cell lung cancer |journal=Expert Opin Pharmacother |volume=11 |issue=8 |pages=1387–402 |date=June 2010 |pmid=20446853 |doi=10.1517/14656566.2010.482560 }} 105. ^{{cite journal | vauthors = Santos FN, de Castria TB, Cruz MR, Riera R | title = Chemotherapy for advanced non-small cell lung cancer in the elderly population | journal = The Cochrane Database of Systematic Reviews | issue = 10 | pages = CD010463 | date = October 2015 | pmid = 26482542 | doi = 10.1002/14651858.CD010463.pub2 }} 106. ^{{cite journal | vauthors = Carbone DP, Felip E | title = Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms | journal = Clinical Lung Cancer | volume = 12 | issue = 5 | pages = 261–71 | date = September 2011 | pmid = 21831720 | doi = 10.1016/j.cllc.2011.06.002 }} 107. ^1 {{cite journal | vauthors = Le Chevalier T | title = Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? | journal = Annals of Oncology | volume = 21 Suppl 7 | issue = Suppl. 7 | pages = vii196–8 | date = October 2010 | pmid = 20943614 | doi = 10.1093/annonc/mdq376 | url = http://annonc.oxfordjournals.org/content/21/suppl_7/vii196.long }} 108. ^{{cite journal | vauthors = Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y | display-authors = 6 | title = Adjuvant chemotherapy for resected early-stage non-small cell lung cancer | journal = The Cochrane Database of Systematic Reviews | issue = 3 | pages = CD011430 | date = March 2015 | pmid = 25730344 | doi = 10.1002/14651858.CD011430 }} 109. ^{{cite journal | vauthors = He J, Shen J, Yang C, Jiang L, Liang W, Shi X, Xu X, He J | title = Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis | journal = Medicine | volume = 94 | issue = 22 | pages = e903 | date = June 2015 | pmid = 26039122 | pmc = 4616365 | doi = 10.1097/MD.0000000000000903 }} 110. ^{{cite journal | title = Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data | journal = Lancet | volume = 383 | issue = 9928 | pages = 1561–71 | date = May 2014 | pmid = 24576776 | pmc = 4022989 | doi = 10.1016/S0140-6736(13)62159-5 | author1 = NSCLC Meta-analysis Collaborative Group }} 111. ^{{cite journal | vauthors = Burdett SS, Stewart LA, Rydzewska L | title = Chemotherapy and surgery versus surgery alone in non-small cell lung cancer | journal = The Cochrane Database of Systematic Reviews | issue = 3 | pages = CD006157 | date = July 2007 | pmid = 17636828 | doi = 10.1002/14651858.CD006157.pub2 }} 112. ^{{cite journal | last1=Noonan | first1=KL | last2=Ho | first2=C | last3=Laskin | first3=J | date=November 2015 | title=The influence of the evolution of first-line chemotherapy on steadily improving survival in advanced non-small-cell lung cancer clinical trials | journal=Journal of Thoracic Oncology | volume=10 | issue=11 | pages=1523–1531 | doi=10.1097/JTO.0000000000000667 | pmid=26536194 }} 113. ^{{cite journal |vauthors=Sörenson S, Glimelius B, Nygren P |title=A systematic overview of chemotherapy effects in non-small cell lung cancer |journal=Acta Oncologica |volume=40 |issue=2–3 |pages=327–39 |year=2001 |pmid=11441939 |doi=10.1080/02841860151116402}} 114. ^{{cite journal |vauthors=Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N |title=A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer |journal=Health Technology Assessment |volume=5 |issue=32 |pages=1–195 |year=2001 |pmid=12065068 |url=http://wrap.warwick.ac.uk/52130/ |deadurl=no |archiveurl=https://web.archive.org/web/20170830234842/http://wrap.warwick.ac.uk/52130/ |archivedate=30 August 2017 |df=dmy-all |doi=10.3310/hta5320 }} 115. ^1 {{cite journal |title=Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials |journal=J. Clin. Oncol. |volume=26 |issue=28|pages=4617–25 |date=October 2008 |pmid=18678835 |pmc=2653127 |doi=10.1200/JCO.2008.17.7162 |author1=NSCLC Meta-Analyses Collaborative Group }} 116. ^{{cite journal|last1=Non-Small Cell Lung Cancer Collaborative|first1=Group|title=Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer.|journal=The Cochrane Database of Systematic Reviews|date=12 May 2010|issue=5|pages=CD007309|pmid=20464750|doi=10.1002/14651858.CD007309.pub2}} 117. ^{{cite journal | vauthors = D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F | title = Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies | journal = Therapeutic Advances in Medical Oncology | volume = 6 | issue = 3 | pages = 101–14 | date = May 2014 | pmid = 24790650 | pmc = 3987652 | doi = 10.1177/1758834014521110 }} 118. ^{{cite book | vauthors = Lazarus DR, Eapen GA | title=Lung Cancer | publisher=Wiley-Blackwell | veditors = Roth JA, Hong WK, Komaki RU | year=2014 | chapter=Chapter 16: Bronchoscopic interventions for lung cancer | edition=4th | isbn=978-1-118-46874-6 }} 119. ^{{cite journal | vauthors = Khemasuwan D, Mehta AC, Wang KP | title = Past, present, and future of endobronchial laser photoresection | journal = Journal of Thoracic Disease | volume = 7 | issue = Suppl 4 | pages = S380–8 | date = December 2015 | pmid = 26807285 | pmc = 4700383 | doi = 10.3978/j.issn.2072-1439.2015.12.55 }} 120. ^{{cite journal | vauthors = Parikh RB, Kirch RA, Smith TJ, Temel JS | title = Early specialty palliative care—translating data in oncology into practice | journal = The New England Journal of Medicine | volume = 369 | issue = 24 | pages = 2347–51 | date = December 2013 | pmid = 24328469 | pmc = 3991113 | doi = 10.1056/nejmsb1305469 }} 121. ^{{cite journal | vauthors = Kelley AS, Meier DE | title = Palliative care—a shifting paradigm | journal = The New England Journal of Medicine | volume = 363 | issue = 8 | pages = 781–2 | date = August 2010 | pmid = 20818881 | doi = 10.1056/NEJMe1004139 }} 122. ^1 {{cite journal | vauthors = Prince-Paul M | title = When hospice is the best option: an opportunity to redefine goals | journal = Oncology | volume = 23 | issue = 4 Suppl Nurse Ed | pages = 13–7 | date = April 2009 | pmid = 19856592 }} 123. ^{{cite journal | vauthors = Ridge CA, McErlean AM, Ginsberg MS | title = Epidemiology of lung cancer | journal = Seminars in Interventional Radiology | volume = 30 | issue = 2 | pages = 93–8 | date = June 2013 | pmid = 24436524 | pmc = 3709917 | doi = 10.1055/s-0033-1342949 }} 124. ^{{cite web | url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/ | title=Lung cancer survival statistics | publisher=Cancer Research UK | deadurl=no | archive-url=https://web.archive.org/web/20141007155320/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/ | archive-date=7 October 2014 | df=dmy-all | date=2015-05-15 }} 125. ^{{cite web|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/#stage|title=Lung cancer survival statistics|publisher=|access-date=28 October 2014|deadurl=no|archive-url=https://web.archive.org/web/20141009015127/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/#stage|archive-date=9 October 2014|df=dmy-all}} 126. ^{{cite journal |url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/|title=Non-Small Cell Lung Cancer Treatment |journal=PDQ for Health Professionals |accessdate=17 November 2015|pmid=26389304|year=2002 |author1=PDQ Adult Treatment Editorial Board }} 127. ^{{Cite book | vauthors = Spiro SG | title=Oxford Textbook Medicine | publisher=OUP Oxford | year=2010 | chapter=18.19.1 | edition=5th | isbn=978-0-19-920485-4 }} 128. ^SEER data (SEER.cancer.gov) Median Age of Cancer Patients at Diagnosis 2002–2003 {{webarchive|url=https://web.archive.org/web/20110516124412/http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.11_2pgs.pdf |date=16 May 2011 }} 129. ^SEER data (SEER.cancer.gov) Median Age of Cancer Patients at Death 2002–2006 {{webarchive|url=https://web.archive.org/web/20110722134255/http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.13_2pgs.pdf |date=22 July 2011 }} 130. ^{{cite journal | vauthors = Slatore CG, Au DH, Gould MK | title = An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes | journal = American Journal of Respiratory and Critical Care Medicine | volume = 182 | issue = 9 | pages = 1195–205 | date = November 2010 | pmid = 21041563 | doi = 10.1164/rccm.2009-038ST | url = http://ajrccm.atsjournals.org/content/182/9/1195.long }} 131. ^{{cite book | last1 = Stewart | first1 = Bernard W. | last2 = Wild | first2 = Christopher P. | name-list-format = vanc |title=World cancer report 2014|date=2014|publisher=IARC Press|location=Lyon|isbn=978-92-832-0429-9|pages=350–352}} 132. ^{{cite journal | vauthors = Proctor RN | title = The history of the discovery of the cigarette-lung cancer link: evidentiary traditions, corporate denial, global toll | journal = Tobacco Control | volume = 21 | issue = 2 | pages = 87–91 | date = March 2012 | pmid = 22345227 | doi = 10.1136/tobaccocontrol-2011-050338 }} 133. ^{{cite journal | vauthors = Lovato C, Watts A, Stead LF | title = Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours | journal = The Cochrane Database of Systematic Reviews | issue = 10 | pages = CD003439 | date = October 2011 | pmid = 21975739 | doi = 10.1002/14651858.CD003439.pub2 }} 134. ^{{cite journal | vauthors = Kemp FB | title = Smoke free policies in Europe. An overview | journal = Pneumologia | volume = 58 | issue = 3 | pages = 155–8 | date = Jul–Sep 2009 | pmid = 19817310 }} 135. ^National Cancer Institute; SEER stat fact sheets: Lung and Bronchus. Surveillance Epidemiology and End Results. 2010 {{webarchive|url=https://web.archive.org/web/20140706152048/http://seer.cancer.gov/statfacts/html/lungb.html|date=6 July 2014}} 136. ^{{cite journal | vauthors = Zhang J, Ou JX, Bai CX | title = Tobacco smoking in China: prevalence, disease burden, challenges and future strategies | journal = Respirology | volume = 16 | issue = 8 | pages = 1165–72 | date = November 2011 | pmid = 21910781 | doi = 10.1111/j.1440-1843.2011.02062.x }} 137. ^{{cite web|title=HONORING VETERANS WITH GOOD HEALTH|url=http://gibbscancercenter.org/news/honoring-veterans-good-health/|accessdate=1 December 2015|date=November 7, 2014|deadurl=yes|archiveurl=https://web.archive.org/web/20151128063005/http://gibbscancercenter.org/news/honoring-veterans-good-health/|archivedate=28 November 2015|df=dmy-all}} 138. ^{{cite web|title=Lung Cancer As It Affects Veterans And Military|url=http://www.lungcanceralliance.org/special-features/special-focus-on-veterans-and-lung-cancer/lung-cancer-and-wartime-exposure.html|accessdate=1 December 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20151208170738/http://www.lungcanceralliance.org/special-features/special-focus-on-veterans-and-lung-cancer/lung-cancer-and-wartime-exposure.html|archivedate=8 December 2015|df=dmy-all}} 139. ^{{cite web | title=Cancer incidence statistics | url=http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One | website=Cancer Research UK | accessdate=20 December 2016 | deadurl=no | archiveurl=https://web.archive.org/web/20170102165540/http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One | archivedate=2 January 2017 | df=dmy-all | date=2015-05-13 }} 140. ^{{cite web | title=Lung cancer statistics | url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/ | website=Cancer Research UK | accessdate=20 December 2016 | deadurl=no | archiveurl=https://web.archive.org/web/20150512144023/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/ | archivedate=12 May 2015 | df=dmy-all | date=2015-05-14 }} 141. ^{{cite journal | vauthors = Kadara H, Kabbout M, Wistuba II | title = Pulmonary adenocarcinoma: a renewed entity in 2011 | journal = Respirology | volume = 17 | issue = 1 | pages = 50–65 | date = January 2012 | pmid = 22040022 | doi = 10.1111/j.1440-1843.2011.02095.x | pmc = 3911779 }} 142. ^{{cite journal | vauthors = Greenberg M, Selikoff IJ | title = Lung cancer in the Schneeberg mines: a reappraisal of the data reported by Harting and Hesse in 1879 | journal = The Annals of Occupational Hygiene | volume = 37 | issue = 1 | pages = 5–14 | date = February 1993 | pmid = 8460878 | doi = 10.1093/annhyg/37.1.5 }} 143. ^{{Cite journal | vauthors = Samet JM | title=Radiation and cancer risk: a continuing challenge for epidemiologists | journal=Environmental Health | volume=10 | issue=Suppl. 1 | pages=S4 |date=April 2011 | pmid=21489214 | doi=10.1186/1476-069X-10-S1-S4 | pmc=3073196}} 144. ^1 2 3 {{cite journal | vauthors = Brahmer JR | title = Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? | journal = Seminars in Oncology | volume = 41 | issue = 1 | pages = 126–32 | date = February 2014 | pmid = 24565586 | pmc = 4732704 | doi = 10.1053/j.seminoncol.2013.12.014 }} 145. ^1 2 3 4 {{cite journal | vauthors = Syn NL, Teng MW, Mok TS, Soo RA | title = De-novo and acquired resistance to immune checkpoint targeting | journal = The Lancet. Oncology | volume = 18 | issue = 12 | pages = e731–e741 | date = December 2017 | pmid = 29208439 | doi = 10.1016/s1470-2045(17)30607-1 }} 146. ^1 {{cite journal | vauthors = Forde PM, Brahmer JR, Kelly RJ | title = New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer | journal = Clinical Cancer Research | volume = 20 | issue = 9 | pages = 2244–8 | date = May 2014 | pmid = 24644000 | pmc = 4325981 | doi = 10.1158/1078-0432.ccr-13-2088 }} 147. ^1 {{cite journal | vauthors = Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C | display-authors = 6 | title = Tracking genomic cancer evolution for precision medicine: the lung TRACERx study | journal = PLoS Biology | volume = 12 | issue = 7 | pages = e1001906 | date = July 2014 | pmid = 25003521 | pmc = 4086714 | doi = 10.1371/journal.pbio.1001906 }} 148. ^TRACERx project, Cancer Research UK science blog {{webarchive|url=https://web.archive.org/web/20141129023515/http://scienceblog.cancerresearchuk.org/2013/07/18/a-new-era-in-lung-cancer-research-the-tracerx-study/ |date=29 November 2014 }} 149. ^{{cite journal | vauthors = Spaans JN, Goss GD | title = Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future | journal = Frontiers in Oncology | volume = 4 | issue = 233 | pages = 233 | date = August 2014 | pmid = 25221748 | pmc = 4145253 | doi = 10.3389/fonc.2014.00233 }} 150. ^{{cite journal | vauthors = Weart TC, Miller KD, Simone CB | title = Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy | journal = Cancer Management and Research | volume = 10 | issue = | pages = 647–652 | date = April 2018 | pmid = 29662327 | pmc = 5892608 | doi = 10.2147/CMAR.S142269 }} 151. ^{{cite journal | vauthors = Prabavathy D, Swarnalatha Y, Ramadoss N | title = Lung cancer stem cells-origin, characteristics and therapy | journal = Stem Cell Investigation | volume = 5 | issue = 6 | pages = 6 | date = March 2018 | pmid = 29682513 | pmc = 5897668 | doi = 10.21037/sci.2018.02.01 }} 152. ^1 2 {{Cite book | first = Greene | last = Frederick L. | name-list-format = vanc | title=AJCC cancer staging manual | publisher=Springer-Verlag | location=Berlin | year=2002 | pages= | isbn=978-0-387-95271-0 |oclc= |doi= |access-date=}} 153. ^1 {{Cite book | vauthors=Peto R, Lopez AD, Boreham J, etal | title=Mortality from smoking in developed countries 1950–2000: Indirect estimates from National Vital Statistics | publisher=Oxford University Press | year=2006 | url=http://www.ctsu.ox.ac.uk/~tobacco/ | isbn=978-0-19-262535-9 | deadurl=no | archive-url=https://web.archive.org/web/20070905151935/http://www.ctsu.ox.ac.uk/~tobacco/ | archive-date=5 September 2007 | df=dmy-all }} 154. ^1 {{cite journal | vauthors = Schick S, Glantz S | title = Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke | journal = Tobacco Control | volume = 14 | issue = 6 | pages = 396–404 | date = December 2005 | pmid = 16319363 | pmc = 1748121 | doi = 10.1136/tc.2005.011288 }} 155. ^1 {{cite web | last=EPA | authorlink=United States Environmental Protection Agency | title=Radiation information: radon | publisher=EPA | date=February 2013 | url=http://www.epa.gov/rpdweb00/radionuclides/radon.html | deadurl=no | archive-url=https://web.archive.org/web/20090429130828/http://www.epa.gov/rpdweb00/radionuclides/radon.html | archive-date=29 April 2009 | df=dmy-all }} 156. ^1 2 3 4 {{cite journal | vauthors = Herbst RS, Heymach JV, Lippman SM | title = Lung cancer | journal = The New England Journal of Medicine | volume = 359 | issue = 13 | pages = 1367–80 | date = September 2008 | pmid = 18815398 | doi = 10.1056/NEJMra0802714 | df = dmy-all }} 157. ^1 {{cite journal | vauthors = Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS | title = K-ras mutations in non-small-cell lung carcinoma: a review | journal = Clinical Lung Cancer | volume = 8 | issue = 1 | pages = 30–8 | date = July 2006 | pmid = 16870043 | doi = 10.3816/CLC.2006.n.030 }} 158. ^1 {{cite journal | vauthors = Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G | title = Small cell lung cancer | journal = Annals of Oncology | volume = 17 Suppl 2 | issue = Suppl. 2 | pages = ii5–10 | date = March 2006 | pmid = 16608983 | doi = 10.1093/annonc/mdj910 }} 159. ^1 {{cite journal | vauthors = Seo JB, Im JG, Goo JM, Chung MJ, Kim MY | title = Atypical pulmonary metastases: spectrum of radiologic findings | journal = Radiographics | volume = 21 | issue = 2 | pages = 403–17 | date = 1 March 2001 | pmid = 11259704 | doi = 10.1148/radiographics.21.2.g01mr17403 | url = http://radiographics.rsnajnls.org/cgi/content/full/21/2/403 | archive-url = https://web.archive.org/web/20071011203717/http://radiographics.rsnajnls.org/cgi/content/full/21/2/403 | df = dmy-all | deadurl = no | archive-date = 11 October 2007 }} 160. ^1 {{cite journal | vauthors = Raz DJ, He B, Rosell R, Jablons DM | title = Bronchioloalveolar carcinoma: a review | journal = Clinical Lung Cancer | volume = 7 | issue = 5 | pages = 313–22 | date = March 2006 | pmid = 16640802 | doi = 10.3816/CLC.2006.n.012 }} 161. ^1 {{cite news | vauthors = Pandey G | title=Bhutan's smokers face public ban | publisher=BBC | date=February 2005 | url=http://news.bbc.co.uk/2/hi/south_asia/4305715.stm | access-date=7 September 2007 | deadurl=no | archive-url=https://web.archive.org/web/20080407045728/http://news.bbc.co.uk/2/hi/south_asia/4305715.stm | archive-date=7 April 2008 | df=dmy-all }} 162. ^1 {{Cite book | vauthors = Arriagada R, Goldstraw P, Le Chevalier T | title=Oxford Textbook of Oncology | publisher=Oxford University Press | year=2002 | page=2094 | edition=2nd | isbn=978-0-19-262926-5 }} 163. ^1 {{cite journal | title = Postoperative radiotherapy for non-small cell lung cancer | journal = The Cochrane Database of Systematic Reviews | volume = 10 | issue = 2 | pages = CD002142 | date = April 2005 | pmid = 15846628 | doi = 10.1002/14651858.CD002142.pub2 | editor1-last = Rydzewska | editor1-first = Larysa | author1 = PORT Meta-analysis Trialists Group | url = http://discovery.ucl.ac.uk/1520973/ }} 164. ^1 {{cite journal | vauthors = Murray N, Turrisi AT | title = A review of first-line treatment for small-cell lung cancer | journal = Journal of Thoracic Oncology | volume = 1 | issue = 3 | pages = 270–8 | date = March 2006 | pmid = 17409868 | doi=10.1016/s1556-0864(15)31579-3}} 165. ^1 {{cite journal | vauthors = Azim HA, Ganti AK | title = Treatment options for relapsed small-cell lung cancer | journal = Anti-Cancer Drugs | volume = 18 | issue = 3 | pages = 255–61 | date = March 2007 | pmid = 17264756 | doi = 10.1097/CAD.0b013e328011a547 }} 166. ^1 {{cite journal | vauthors = MacCallum C, Gillenwater HH | title = Second-line treatment of small-cell lung cancer | journal = Current Oncology Reports | volume = 8 | issue = 4 | pages = 258–64 | date = July 2006 | pmid = 17254525 | doi = 10.1007/s11912-006-0030-8 }} 167. ^1 2 {{cite journal | vauthors = Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N | title = Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review | journal = Thorax | volume = 57 | issue = 1 | pages = 20–8 | date = January 2002 | pmid = 11809985 | pmc = 1746188 | doi = 10.1136/thorax.57.1.20 }} 168. ^1 {{cite web |title=Small Cell Lung Cancer Treatment |publisher=National Cancer Institute |url=http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional |work=PDQ for Health Professionals |year=2012 |access-date=16 May 2012 |deadurl=no |archive-url=https://web.archive.org/web/20120513015218/http://cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional |archive-date=13 May 2012 |df=dmy-all }} 169. ^1 {{cite journal | vauthors = Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ | title = Cancer statistics, 2004 | journal = Ca | volume = 54 | issue = 1 | pages = 8–29 | year = 2004 | pmid = 14974761 | doi = 10.3322/canjclin.54.1.8 }} 170. ^1 {{cite journal | vauthors = Lum KL, Polansky JR, Jackler RK, Glantz SA | title = Signed, sealed and delivered: "big tobacco" in Hollywood, 1927-1951 | journal = Tobacco Control | volume = 17 | issue = 5 | pages = 313–23 | date = October 2008 | pmid = 18818225 | pmc = 2602591 | doi = 10.1136/tc.2008.025445 | url = http://tobaccocontrol.bmj.com/cgi/content/full/17/5/313 | archive-url = https://web.archive.org/web/20090404085818/http://tobaccocontrol.bmj.com/cgi/content/full/17/5/313 | df = dmy-all | deadurl = no | archive-date = 4 April 2009 }} 171. ^1 {{cite web | title=Gender in lung cancer and smoking research | publisher=World Health Organization | year=2004 | url=http://www.who.int/gender/documents/en/lungcancerlow.pdf | access-date=26 May 2007 | deadurl=no | archive-url=https://web.archive.org/web/20070614013951/http://www.who.int/gender/documents/en/lungcancerlow.pdf | archive-date=14 June 2007 | df=dmy-all }} 172. ^1 {{cite journal | vauthors = Behera D, Balamugesh T | title = Lung cancer in India | journal = The Indian Journal of Chest Diseases & Allied Sciences | volume = 46 | issue = 4 | pages = 269–81 | year = 2004 | pmid = 15515828 | url = http://www.vpci.org.in/upload/Journals/pic130.pdf#page=27 | format = PDF | archive-url = https://web.archive.org/web/20081217024508/http://www.vpci.org.in/upload/Journals/pic130.pdf#page=27 | df = dmy-all | deadurl = no | archive-date = 17 December 2008 }} 173. ^1 {{cite journal | vauthors = Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H | title = The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma | journal = International Journal of Epidemiology | volume = 26 | issue = 1 | pages = 14–23 | date = February 1997 | pmid = 9126499 | doi = 10.1093/ije/26.1.14 | url = http://ije.oxfordjournals.org/cgi/reprint/26/1/14 | archive-url = https://web.archive.org/web/20081205204700/http://ije.oxfordjournals.org/cgi/reprint/26/1/14 | df = dmy-all | deadurl = no | archive-date = 5 December 2008 }} 174. ^1 {{Cite book | last=Morgagni | first=Giovanni Battista | name-list-format = vanc | title=De sedibus et causis morborum per anatomen indagatis | year=1761 |ol=24830495M }} 175. ^1 {{Cite book | last=Bayle | first=Gaspard-Laurent | name-list-format = vanc | title=Recherches sur la phthisie pulmonaire |place=Paris |language=French | year=1810 |ol=15355651W }} 176. ^1 2 {{cite journal | vauthors = Witschi H | title = A short history of lung cancer | journal = Toxicological Sciences | volume = 64 | issue = 1 | pages = 4–6 | date = November 2001 | pmid = 11606795 | doi = 10.1093/toxsci/64.1.4 | url = http://toxsci.oxfordjournals.org/cgi/content/full/64/1/4 | archive-url = https://web.archive.org/web/20070309064452/http://toxsci.oxfordjournals.org/cgi/content/full/64/1/4 | df = dmy-all | deadurl = no | archive-date = 9 March 2007 }} 177. ^1 {{Cite book | vauthors = Adler I | year=1912 | title=Primary Malignant Growths of the Lungs and Bronchi | place= New York | publisher=Longmans, Green, and Company | oclc=14783544 | ol=24396062M }}, cited in {{cite journal | vauthors = Spiro SG, Silvestri GA | title = One hundred years of lung cancer | journal = American Journal of Respiratory and Critical Care Medicine | volume = 172 | issue = 5 | pages = 523–9 | date = September 2005 | pmid = 15961694 | doi = 10.1164/rccm.200504-531OE }} 178. ^1 {{cite web | vauthors = Grannis FW |title=History of cigarette smoking and lung cancer | publisher=smokinglungs.com | url=http://www.smokinglungs.com/cighist.htm | access-date=6 August 2007 | archive-url = https://web.archive.org/web/20070718174754/http://www.smokinglungs.com/cighist.htm| archive-date = 18 July 2007}} 179. ^1 {{Cite book | vauthors = Proctor R | title=The Nazi War on Cancer | publisher=Princeton University Press | year=2000 | pages=173–246 | isbn=978-0-691-00196-8 }} 180. ^1 {{cite journal | vauthors = Doll R, Hill AB | title = Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors | journal = British Medical Journal | volume = 2 | issue = 5001 | pages = 1071–81 | date = November 1956 | pmid = 13364389 | pmc = 2035864 | doi = 10.1136/bmj.2.5001.1071 }} 181. ^1 {{cite web | author=US Department of Health Education and Welfare | title=Smoking and health: report of the advisory committee to the Surgeon General of the Public Health Service | location=Washington, DC | publisher=US Government Printing Office | year=1964 | url=http://profiles.nlm.nih.gov/NN/B/B/M/Q/_/nnbbmq.pdf | deadurl=no | archive-url=https://web.archive.org/web/20081217024606/http://profiles.nlm.nih.gov/NN/B/B/M/Q/_/nnbbmq.pdf | archive-date=17 December 2008 | df=dmy-all }} 182. ^1 2 {{Cite book | vauthors = Greaves M | title=Cancer: the Evolutionary Legacy | publisher=Oxford University Press | year=2000 | pages=196–197 | isbn=978-0-19-262835-0 }} 183. ^1 {{cite journal | vauthors = Horn L, Johnson DH | title = Evarts A. Graham and the first pneumonectomy for lung cancer | journal = Journal of Clinical Oncology | volume = 26 | issue = 19 | pages = 3268–75 | date = July 2008 | pmid = 18591561 | doi = 10.1200/JCO.2008.16.8260 | url = http://jco.ascopubs.org/cgi/pdf_extract/26/19/3268 }} 184. ^1 {{cite journal | vauthors = Edwards AT | title = Carcinoma of the bronchus | journal = Thorax | volume = 1 | issue = 1 | pages = 1–25 | date = March 1946 | pmid = 20986395 | pmc = 1018207 | doi = 10.1136/thx.1.1.1 }} 185. ^1 {{cite journal | vauthors = Kabela M | title = [Experience with radical irradiation of bronchial cancer] | language = German | journal = Ceskoslovenska Onkologia | volume = 3 | issue = 2 | pages = 109–15 | year = 1956 | pmid = 13383622 | trans-title = Experience with radical irradiation of bronchial cancer }} 186. ^1 {{cite journal | vauthors = Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M | title = Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee | journal = Lancet | volume = 350 | issue = 9072 | pages = 161–5 | date = July 1997 | pmid = 9250182 | doi = 10.1016/S0140-6736(97)06305-8 }} 187. ^1 {{cite journal | vauthors = Lennox SC, Flavell G, Pollock DJ, Thompson VC, Wilkins JL | title = Results of resection for oat-cell carcinoma of the lung | journal = Lancet | volume = 2 | issue = 7575 | pages = 925–7 | date = November 1968 | pmid = 4176258 | doi = 10.1016/S0140-6736(68)91163-X }} 188. ^1 {{cite journal | vauthors = Miller AB, Fox W, Tall R | title = Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus | journal = Lancet | volume = 2 | issue = 7619 | pages = 501–5 | date = September 1969 | pmid = 4184834 | doi = 10.1016/S0140-6736(69)90212-8 }} 189. ^1 {{cite journal | vauthors = Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna JD | title = Intensive chemotherapy of small cell bronchogenic carcinoma | journal = Cancer Treatment Reports | volume = 61 | issue = 3 | pages = 349–54 | year = 1977 | pmid = 194691 }} }} External links{{Medical resources|DiseasesDB = 7616 |ICD10 = {{ICD10|C|33||c|30}}-{{ICD10|C|34||c|30}} |ICD9 = {{ICD9|162}} |ICDO = |OMIM =211980 |MedlinePlus = 007194 |eMedicineSubj = med |eMedicineTopic = 1333 |eMedicine_mult = {{eMedicine2|med|1336}} {{eMedicine2|emerg|335}} {{eMedicine2|radio|807}} {{eMedicine2|radio|405}} {{eMedicine2|radio|406}} |MeshID = D002283 }}{{commons category|Cancers of bronchus and lung}}{{wikiquote}}
3 : Lung cancer|Health effects of tobacco|RTT(full) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 随便看 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。